RS65681B1 - Postupci, upotrebe i sastavi za lečenje rifabutinom - Google Patents

Postupci, upotrebe i sastavi za lečenje rifabutinom

Info

Publication number
RS65681B1
RS65681B1 RS20240688A RSP20240688A RS65681B1 RS 65681 B1 RS65681 B1 RS 65681B1 RS 20240688 A RS20240688 A RS 20240688A RS P20240688 A RSP20240688 A RS P20240688A RS 65681 B1 RS65681 B1 RS 65681B1
Authority
RS
Serbia
Prior art keywords
rifabutin
baumannii
fhue
solvent
composition
Prior art date
Application number
RS20240688A
Other languages
English (en)
Serbian (sr)
Inventor
Glenn E Dale
Sergio Lociuro
Christian Kemmer
Vincent Trebosc
Marc Gitzinger
Original Assignee
BioVersys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioVersys AG filed Critical BioVersys AG
Publication of RS65681B1 publication Critical patent/RS65681B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20240688A 2019-09-12 2020-08-03 Postupci, upotrebe i sastavi za lečenje rifabutinom RS65681B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US202062977659P 2020-02-17 2020-02-17
EP20768692.4A EP4028001B1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions
PCT/IB2020/000647 WO2021048611A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Publications (1)

Publication Number Publication Date
RS65681B1 true RS65681B1 (sr) 2024-07-31

Family

ID=72432957

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240688A RS65681B1 (sr) 2019-09-12 2020-08-03 Postupci, upotrebe i sastavi za lečenje rifabutinom

Country Status (17)

Country Link
US (6) US11207305B2 (enExample)
EP (3) EP4420673A3 (enExample)
JP (4) JP7769605B2 (enExample)
KR (1) KR20220103698A (enExample)
CN (3) CN120860031A (enExample)
AU (2) AU2020344214B2 (enExample)
BR (2) BR112022004645A2 (enExample)
CA (2) CA3154129A1 (enExample)
ES (1) ES2982067T3 (enExample)
HR (1) HRP20240818T1 (enExample)
HU (1) HUE066936T2 (enExample)
MX (1) MX2022003077A (enExample)
PH (1) PH12022550610A1 (enExample)
PL (1) PL4028001T3 (enExample)
RS (1) RS65681B1 (enExample)
SM (1) SMT202400250T1 (enExample)
WO (2) WO2021048611A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
CA2714043C (en) * 2008-02-08 2016-11-08 Giaconda Limited Methods and compositions for treating inflammatory bowel disease
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
EP2670417A4 (en) * 2011-01-31 2014-07-09 Us Army METHOD AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS WITH IRON RADIATORS
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
WO2016013986A1 (en) * 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
HK1243740A1 (zh) * 2014-09-04 2018-07-20 Labrador Diagnostics Llc 病原体和抗微生物剂抗性检测
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
JP7072898B2 (ja) * 2016-08-16 2022-05-23 ユニバーシティ オブ ロチェスター ポリミキシンｂ／トリメトプリム系の治療薬を含有する医薬組成物
AU2018219149A1 (en) * 2017-02-07 2019-09-19 Unm Rainforest Innovations Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) * 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Also Published As

Publication number Publication date
HRP20240818T1 (hr) 2024-10-11
AU2020347536B2 (en) 2025-09-25
JP7804570B2 (ja) 2026-01-22
US12257241B2 (en) 2025-03-25
ES2982067T3 (es) 2024-10-14
PL4028001T3 (pl) 2024-07-22
MX2022003077A (es) 2022-07-11
US20240041845A1 (en) 2024-02-08
JP2026016690A (ja) 2026-02-03
EP4420673A2 (en) 2024-08-28
US20210077471A1 (en) 2021-03-18
EP4028000A1 (en) 2022-07-20
US20220184048A1 (en) 2022-06-16
WO2021048610A1 (en) 2021-03-18
US20210077472A1 (en) 2021-03-18
PH12022550610A1 (en) 2023-03-13
CA3154317A1 (en) 2021-03-18
AU2020344214A1 (en) 2022-04-21
JP2022548252A (ja) 2022-11-17
CN120860031A (zh) 2025-10-31
BR112022004645A2 (pt) 2022-06-21
CA3154129A1 (en) 2021-03-18
KR20220103698A (ko) 2022-07-22
US11766425B2 (en) 2023-09-26
SMT202400250T1 (it) 2024-07-09
CN114980889A (zh) 2022-08-30
CN115052597A (zh) 2022-09-13
AU2020344214B2 (en) 2026-01-22
US11833139B2 (en) 2023-12-05
US20230132691A1 (en) 2023-05-04
CN115052597B (zh) 2025-07-08
US11351158B2 (en) 2022-06-07
HUE066936T2 (hu) 2024-09-28
EP4420673A3 (en) 2024-11-06
EP4028001C0 (en) 2024-04-10
EP4028001B1 (en) 2024-04-10
AU2020347536A1 (en) 2022-04-14
JP2022551228A (ja) 2022-12-08
BR112022004672A2 (pt) 2022-06-07
WO2021048611A1 (en) 2021-03-18
EP4028001A1 (en) 2022-07-20
JP7769605B2 (ja) 2025-11-13
JP2025176113A (ja) 2025-12-03
US11207305B2 (en) 2021-12-28
US20250281469A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
Cotroneo et al. In vitro and in vivo characterization of tebipenem, an oral carbapenem
Zhang et al. The role of LpxA/C/D and pmrA/B gene systems in colistin-resistant clinical strains of Acinetobacter baumannii
US20230381157A1 (en) Rifabutin for the treatment of acinetobacter baumannii
EP1771558A2 (en) Inhibition of biofilm formation
Wang et al. Arabinosyltransferase C mediates multiple drugs intrinsic resistance by altering cell envelope permeability in Mycobacterium abscessus
Xiao et al. Novel small-molecule compound YH7 inhibits the biofilm formation of Staphylococcus aureus in a sarX-dependent manner
JP2026016690A (ja) リファブチン処置法、使用および組成物
Vila Fluoroquinolone resistance
Zhang et al. Alnustone inhibits Streptococcus pneumoniae virulence by targeting pneumolysin and sortase A
US20230355597A1 (en) Compounds, compositions, and methods for the treatment and prevention of avian pathogenic e. coli (apec)
HK40115867A (en) Rifabutin treatment methods, uses, and compositions
US20240041950A1 (en) Decolonization of enterobacteria, such as klebsiella pneumoniae, from the gut using strains of klebsiella oxytoca
US20210330603A1 (en) Methods of using cannabinoids for inhibiting induction of virulence in enteric pathogens
EP1549143A2 (en) Antibacterial pyrazole carboxylic acid hydrazides
Castañeda-Meléndrez et al. Genomic characterization of a multidrug-resistant uropathogenic Escherichia coli and evaluation of Echeveria plant extracts as antibacterials
Mateus et al. RND efflux systems contribute to resistance and virulence of Aliarcobacter butzleri. Antibiotics 2021; 10: 823
Gao et al. Antivirulence Agent as an Adjuvant of β-Lactam Antibiotics in Treating KAO Infections. Antibiotics 2022, 11, 819
KR20230085579A (ko) 항병원성 활성 및 바이오필름 형성 억제 효과를 나타내는 화합물의 신규한 용도
Mutuku Molecular Characterization And Antimicrobial Resistance Patterns Of Enterococcus Species Isolated From Patients Attending Aga Khan Hospital, Nairobi, Kenya.
Poza et al. Pneumonia infection in mice reveals the involvement of the feoA gene in the pathogenesis of Acinetobacter baumannii
CN106890167A (zh) 一种具有抗结核活性的化合物及其应用
KR20220151426A (ko) 병원성 비브리오균의 병원성인자 발현 억제용 약학적 조성물
WO2018070874A1 (en) Means and methods for reducing or avoiding antibiotic resistance and spread of virulence in human pathogens
Dzink‐Fox et al. Identification of Mar mutants among clinical bacterial isolates
JP2003523754A (ja) グラム陽性エンテロコッカスビルレンス因子のスクリーニング法